Aura Biosciences, Inc.: management transactions · United States · SEC (Form 4)

About Aura Biosciences, Inc.

Aura Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company listed on the NASDAQ under the ticker AURA. Headquartered in Boston, Massachusetts, and incorporated in Delaware in 2009, Aura is focused on developing a novel class of targeted oncology therapies designed to preserve organ function while treating cancer. That positioning matters in a field where standard-of-care treatments can be highly invasive and may permanently damage healthy tissue, especially in hard-to-treat localized tumors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001501796/000119312526130401/aura-20251231.htm?utm_source=openai)) The company’s core platform is built around virus-like drug conjugates, or VDCs, a targeted delivery approach intended to concentrate therapeutic activity on tumor cells. Aura’s lead asset is bel-sar, previously referenced as AU-011, which is being developed first in ocular oncology, particularly for choroidal melanoma, a rare and potentially vision- and life-threatening eye cancer. The company is also expanding the platform into additional ophthalmic settings and into urologic oncology, with a notable focus on non-muscle-invasive bladder cancer (NMIBC). This broader pipeline is strategically important because it gives Aura multiple shots on goal beyond a single rare-disease indication. ([aurabiosciences.com](https://www.aurabiosciences.com/pipeline-programs/pipeline/?utm_source=openai)) From a competitive standpoint, Aura is differentiated by its precision-oncology strategy aimed at high unmet-need tumors where existing therapies may be destructive or suboptimal. In choroidal melanoma, management has historically relied on radiotherapy approaches that can preserve life but often at a substantial cost to vision. Aura’s value proposition is to potentially shift the treatment paradigm toward a less invasive, organ-preserving option. At the same time, the business remains high risk: Aura is still a clinical-stage company, has no approved products, and has not generated product revenue to date according to its latest SEC filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001501796/000119312526130401/aura-20251231.htm?utm_source=openai)) Geographically, Aura is primarily a United States company with clinical and corporate operations centered in Boston and trial activity tied to specialized oncology centers. Recent milestones include continued advancement of the global Phase 3 CoMpass trial in early-stage choroidal melanoma, positive Phase 2 end-of-study data, and the release of full-year 2025 financial results in March 2026. The company has also highlighted formulation progress and the potential to extend bel-sar into non-ocular solid tumors, starting with urologic oncology. For international investors, AURA is best viewed as a differentiated, innovation-led biotech name on the NASDAQ, with meaningful upside tied to clinical execution but also substantial financing and regulatory risk. ([ir.aurabiosciences.com](https://ir.aurabiosciences.com/news-releases/news-release-details/aura-biosciences-reports-fourth-quarter-and-full-year-2025?utm_source=openai))